Table 1 Four patients with advanced chordoma treated with EGFR targeting therapy
Ref. | Sex | Location of primary tumor | Date of initial diagnosis | Date of beginning of EGFR-targeting therapy | Tumor locations | Patient's age | Therapy | Tumor response | Duration of response |
|---|---|---|---|---|---|---|---|---|---|
[8] | M | Sacral | 2001 | 2005 | Local relapse, Inguinal lymph node, and lung metastases | 52 | Cetuximab-Gefitinib | « Significant regression » of all lesions after 2 months* | Ongoing after 9 months |
[9] | F | Cervical | 1996 | 2007 | Local relapse | 75 | Cetuximab-Gefitinib | Regression by 44% of the volume after 4 months | Ongoing after 4 months |
[10] | M | Sacral | 2004 | 2008 | Gluteal mass and iliac lymph nodes | 57 | Erlotinib | Partial response superior to 30% reduction in tumor bulk after 3 months | Ongoing after 11 months |
Our case | M | Sacral | 1999 | 2010 | Lung metastases, cervical lymph node and thoracic soft tissue mass | 76 | Erlotinib | Regression of the thoracic lesion by 53% of the volume after 3 months, by 70% after 7 months. | 12 months |